Form 4 for BMRN BIOMARIN PHARMACEUTICAL INC
Accepted 2023-01-27 00:00:00 ET · period of report 2023-01-25 · accession 0001567619-23-001396 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-01-27 | 2023-01-25 | BMRN | Ajer Jeffrey Robert | EVP, Chief Commercial Off | S - Sale+OE | $115.69 | -49.0K | 45.3K | -52% | -$5.67M |
| D | 2023-01-27 | 2023-01-25 | BMRN | Ajer Jeffrey Robert | EVP, Chief Commercial Off | M - OptEx | $67.81 | +49.0K | 90.1K | +119% | +$3.32M |
| DM | 2023-01-27 | 2023-01-25 | BMRN | Ajer Jeffrey Robert | EVP, Chief Commercial Off | M - OptEx | $0.00 | -49.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-25 | S | D | 4,175 | $116.15 | 41,088 | D | — | — | (F1) Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. (F3) The price in column 4 is the weighted average price. The price actually received ranged from $116.000 to $116.485. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
| 2 | Common | Common Stock | 2023-01-25 | S | D | 44,825 | $115.65 | 45,263 | D | — | — | (F1) Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. (F2) The price in column 4 is the weighted average price. The price actually received ranged from $115.000 to 115.998. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price. |
| 3 | Common | Common Stock | 2023-01-25 | M | A | 49,000 | $67.81 | 90,088 | D | — | — | (F1) Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. |
| 4 | Derivative | Stock Option (Right to buy Common Stock) | 2023-01-25 | M | D | 2,200 | $0.00 | 0 | D | $67.81 · 2013-11-15 to 2023-05-14 | 2,200 Common Stock | (F1) Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. (F4) Reflects the number of options outstanding after the transactions from this specific stock option grant. |
| 5 | Derivative | Stock Option (Right to buy Common Stock) | 2023-01-25 | M | D | 46,800 | $0.00 | 0 | D | $67.81 · 2013-11-15 to 2023-05-14 | 46,800 Common Stock | (F1) Trade made pursuant to a 10b5-1 plan executed on February 28, 2022. (F4) Reflects the number of options outstanding after the transactions from this specific stock option grant. |